Back to search results

REVIVE: Tai Chi/Qigong for Women with Mobility Impairments

The REVIVE study is looking at how a seated Tai Chi/Qigong (TCQ) program can help women aged 35-64 with mobility impairments. This program, called Accessible Tai Chi/Qigong, involves daily video sessions with gentle movements, breathing, and relaxation. It's compared to another program with daily health education videos. The study aims to see if Tai Chi/Qigong can improve health measures like waist size, heart rate variability (a measure of how your heart adapts to stress), and stress hormones (salivary cortisol). You can join if you are a woman between 35 and 64, have had a mobility impairment for at least a year, use a mobility aid, live in the community, and can move your upper body enough for seated exercises. The study is currently unclear on its recruitment status and plans to enroll 280 participants.

Study design
This is a fully remote study where 280 participants will be randomly assigned to either the Tai Chi/Qigong group or the health education video group.
What's involved
You will participate in study activities from home for about 30 weeks, including a 12-week guided intervention phase and assessments at the beginning, after 15 weeks, and after 29 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 29 weeks after the start of the study, with a final assessment at that time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07675681

REmote Virtual Inspiration: Vitality and Energy

Recruiting
NAAges 35–64InterventionalTreatment
Arizona State University
~280 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:Accesible Tai Chi/Qigong (TCQ)Health Education Videos (HEV)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Waist Circumference (cm)
Measured over Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
+2 more outcomes measured

Conditions

Implementation Science
Women Health
Disability Physical
Meditation
Tai Chi

Explore related trials

Cardiometabolic DiseaseImpaired MobilityPhysical handicapSleep DisorderStress

Where it's being run

1 sites across 1 states
Arizona1

Who to contact

Rebecca E Lee, PhD
[email protected]
6024960910
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Self-identify as a woman.
Age 35-64 years.
Mobility impairment lasting at least 1 year.
Regular use of a mobility aid (e.g., wheelchair, scooter, walker, cane, crutches, or other assistive device).
Community dwelling.
Able to demonstrate sufficient upper-extremity mobility to participate in seated Tai Chi/Qigong activities.
Access to a smartphone, tablet, or computer with internet access.
Willing to wear a study-provided wearable device and complete study assessments.
Reside in the United States.
Waist circumference ≥ 33 inches (84 cm).
Perceived Stress Scale (PSS) score ≥ 15.
Insomnia Severity Index (ISI) score ≥ 8.
Emotional eating indicated by a score \< 3 on the Mindful Eating Questionnaire (MEQ) Emotional Response subscale.
Able to understand written and spoken English.
Able to provide informed consent.
Able to provide healthcare provider approval for participation.

Exclusion

Medical conditions that would make participation unsafe, as determined during screening.
Inability to safely perform seated upper-body movements.
Current participation in a structured Tai Chi, Qigong, or similar meditative movement program.
Pregnancy, lactation, or plans to become pregnant during the study period.
Cognitive, visual, auditory, or other impairments that would preclude completion of study procedures.
Implanted cardiac devices or implanted electronic devices that interfere with physiologic measurements.
Severe arrhythmia, left ventricular assist device (LVAD), or other conditions that interfere with heart rate variability assessment.
Use of sleep medications three or more times per week.
Medical conditions or medications that substantially affect autonomic nervous system activity, sleep, or stress-related outcomes.
Uncontrolled cardiovascular, neurological, psychiatric, or other serious medical conditions that would preclude safe participation.

What this trial measures

  • Waist Circumference (cm)Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)

    Change in waist circumference measured in centimeters using a standardized Zoom-guided measurement protocol. Waist circumference is used as an indicator of abdominal adiposity and cardiometabolic risk.

  • High-Frequency Heart Rate Variability (HF Power)Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.

    Change in nocturnal high-frequency (HF) heart rate variability power measured using the Oura Ring. Higher HF power indicates greater parasympathetic nervous system activity and autonomic balance. HF power is the primary heart rate variability parameter used to assess physiological stress regulation.

  • Diurnal Salivary Cortisol Area Under the Curve (AUCg)Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)

    Change in diurnal salivary cortisol area under the curve with respect to ground (AUCg), calculated from saliva samples collected over two days with three samples per day. Lower AUCg values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activation and biological stress.